For Cutting-Edge Stem Cell Work, California Billions Still Unmatched
This article was originally published in Start Up
California’s stem cell agency still has nearly two billion dollars to grant. But with recent stem cell breakthroughs slow to translate, will venture backers and drug firms help build the ecosystem California citizens imagined in 2004 when they voted to make the state a beacon for the science?
You may also be interested in...
The company hopes its newest division will mirror the growth of its rare disease unit, which was built largely through aggressive business development.
The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.